NCT06191900TerminatedNot Applicable
Single Arm Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT201) in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)
Grit Biotechnology1 site in 1 country4 target enrollmentStarted: June 5, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Incidence and severity of adcersed events per CTCAE 5.0
Study Overview
Brief Summary
This study is an early exploration clinical study with one arm.
The study consists of two stages, namely the dose escalation stage and the dose extension stage:
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •1. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), must have the ability to understand the requirements of the study;
- •2.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. The separated tissues mass weighing ≥1.0g (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible;
Exclusion Criteria
- •1.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (>10 mg/day of prednisone or equivalent hormone);
- •2. Arterial/venous thrombotic events within 3 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring;
- •3.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever > 38.5℃ occurring during the screening period, except for tumor fever;
- •4. Patients who have received allogeneic bone marrow transplantation or an organ allograft;
- •5.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);
Arms & Interventions
GT201 treatment group
Experimental
Intervention: Autologous tumor infiltrating lymphocyte injection（GT201） (Biological)
Outcomes
Primary Outcomes
Incidence and severity of adcersed events per CTCAE 5.0
Time Frame: 3 years
To characterize the safety profile of autologous TIL injection（GT201) in patients with relapsed/metastatic advanced solid tumor as measured by the incidence and severity of adcersed events per CTCAE 5.0
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Not Applicable
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)Solid TumorGynecological TumorsNCT06145802Grit Biotechnology36
Recruiting
Not Applicable
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck TumorsHNSCCNCT06190275Grit Biotechnology32
Recruiting
Phase 1
Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological TumorsMetastatic or Recurrent Gynecological TumorsNCT05238818XinWu36
Not yet recruiting
Early Phase 1
An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT04919616Shanghai OriginCell Therapeutics Co., Ltd.15
Recruiting
Not Applicable
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung CancerAdultLung CancerNCT06519669Grit Biotechnology40